Clinical Trial

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

A new clinical study compares a powered prosthetic knee against current tech, promising to reduce effort and revolutionize mobility for amputees.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

Amid a major leadership change, Sonorous Neurovascular pushes its pioneering BosSTENT™ for pulsatile tinnitus sufferers closer to market approval.

Eurofins Viracor's new assay delivers rapid insights into CAR T-cell performance, promising faster, more personalized decisions for cancer patients.

Tanabe Pharma Canada's 'Letters to ALS' offers a raw, intimate look into the fight against the disease, strengthening community bonds through shared stories.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

Aerin Medical's milestone highlights a major shift toward minimally invasive, in-office treatments for chronic nasal issues, moving beyond traditional surgery.

A new FDA-cleared device uses water vapor to ablate prostate tissue, showing high efficacy in trials while minimizing life-altering side effects.

Riding high on record 2025 results and a new FDA approval, LivaNova faces intense scrutiny ahead of its May 6 earnings call. Can it sustain the momentum?

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

The scientist behind PARP inhibitors is backing a new approach. Dr. Alan Ashworth's appointment at Leapfrog Bio signals a major push in precision oncology.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.